VIVUS INC Form 8-K August 02, 2010

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

July 31, 2010

VIVUS, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)

001-33389 (Commission File Number)

94-3136179 (IRS Employer Identification No.)

1172 CASTRO STREET

MOUNTAIN VIEW, CA 94040


(Address of principal executive offices, including zip code)

(650) 934-5200

(Registrant s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)



- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure

On July 31, 2010, A. Julian Muñoz, M.D., from The Division of Metabolism, Endocrinology & Diabetes at the University of Michigan, delivered an oral presentation entitled: Weight Loss With Low-Dose, Controlled-Release Phentermine/Topiramate in African American Subjects vs Non-African American Subjects: Pooled 1-Year Data from Two Phase 3 Trials at the 2010 National Medical Association Annual Convention and Scientific Assembly in Orlando, Florida.

A copy of the slides presented by Dr. Muñoz is attached hereto as Exhibit 99.1.

The information in this Current Report on Form 8-K and the exhibit attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or incorporated by reference into any of the Registrant s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Description

99.1 Slide presentation dated July 31, 2010, entitled Weight Loss With Low-Dose, Controlled-Release Phentermine/Topiramate in African American Subjects vs Non-African American Subjects: Pooled 1-Year Data from Two Phase 3 Trials

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VIVUS, INC.

By: /s/ Lee B. Perry
Lee B. Perry
Vice President and Chief Accounting Officer

Date: July 31, 2010

3

EXHIBIT INDEX

Exhibit No. Description

99.1 Slide presentation dated July 31, 2010, entitled Weight Loss With Low-Dose, Controlled-Release Phentermine/Topiramate in African American Subjects vs Non-African American Subjects: Pooled 1-Year Data from Two Phase 3 Trials

4